Zobrazeno 1 - 10
of 656
pro vyhledávání: '"D. A. Fletcher"'
Autor:
Sanhong Yu, Lynette M Sholl, Stephanie Siegmund, Thomas M Ulbright, Katrina Collins, Maurizio Colecchia, Maria del Pilar Gonzalez‐Peramato, Květoslava Michalová, Jennifer B Gordetsky, Kristine M Cornejo, Chia‐Sui Kao, Sara E Wobker, Sara O Vargas, Fiona Maclean, Muhammad T Idrees, William J Anderson, Christopher D M Fletcher, Andres M Acosta
Publikováno v:
Histopathology. 82:1079-1088
Publikováno v:
Histopathology. 82:83-94
Mesenchymal lesions of the breast are a heterogeneous range of entities with diverse clinical, histological, and molecular features, as well as biological behaviour. Their morphologic overlap with non-mesenchymal lesions (such as metaplastic carcinom
Autor:
David J, Papke, Brendan C, Dickson, Andre M, Oliveira, Lynette M, Sholl, Christopher D M, Fletcher
Publikováno v:
American Journal of Surgical Pathology. 47:12-24
Recently, it has been recognized that a subset of primary soft tissue neoplasms with GLI1 gene alterations exhibit nested architecture and can mimic glomus tumors or well-differentiated neuroendocrine tumors. Here, we report a series of 20 such neopl
Autor:
David J, Papke, Jyothi, Jagannathan, Fei, Dong, Brendan C, Dickson, Fredrik, Mertens, Jason L, Hornick, Christopher D M, Fletcher
Publikováno v:
American Journal of Surgical Pathology. 47:147-156
Epithelioid and spindle cell hemangioma was initially described in 1999 in a series of primary bone tumors and was subsequently suggested by some to represent a variant of epithelioid hemangioma. Here, we studied 18 epithelioid and spindle cell heman
Autor:
William J, Anderson, Fredrik, Mertens, Adrián, Mariño-Enríquez, Jason L, Hornick, Christopher D M, Fletcher
Publikováno v:
American Journal of Surgical Pathology. 46:1329-1339
Superficial CD34-positive fibroblastic tumor (SCD34FT) is a rare soft tissue neoplasm that shows overlapping features with PRDM10 -rearranged soft tissue tumor ( PRDM10 -STT). This study characterizes the clinicopathologic, immunohistochemical, and m
Autor:
Danielle, Costigan, Paola, Dal Cin, Christopher D M, Fletcher, Marisa R, Nucci, Carlos, Parra-Herran, David B, Chapel
Publikováno v:
American Journal of Surgical Pathology. 46:1196-1206
Low-grade fibromyxoid sarcoma (LGFMS) is a malignancy with propensity for late relapse that principally affects deep soft tissues of the extremities and trunk. Its occurrence in the lower female genital tract is rare, and thus it may not be always co
Autor:
Judith V M G Bovée, Fleur Webster, Fernanda Amary, Daniel Baumhoer, J L (Hans) Bloem, Julia A Bridge, Justin M M Cates, Enrique de Alava, Angelo Paolo Dei Tos, Kevin B Jones, Annabelle Mahar, G Petur Nielsen, Alberto Righi, Andrew J Wagner, Akihiko Yoshida, Christopher D M Fletcher
Publikováno v:
Histopathology, 82(4), 531-540. WILEY
Background and objectives: Bone tumours are relatively rare and, as a consequence, treatment in a centre with expertise is required. Current treatment guidelines also recommend review by a specialised pathologist. Here we report on international cons
Autor:
Jason L Hornick, Fleur Webster, Angelo Paolo Dei Tos, Chris Hemmings, Markku Miettinen, Yoshinao Oda, Chandrajit P Raut, Brian P Rubin, Margaret Von Mehren, Eva Wardelmann, Christopher D M Fletcher
Publikováno v:
HistopathologyReferences.
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract and are among the most frequent sarcomas. Accurate diagnosis, classification, and reporting are critical for prognostication and patient ma
Autor:
William J Anderson, Lynette M Sholl, Christopher D M Fletcher, Stephanie Schulte, Li Juan Wang, Fiona M Maclean, Michelle S Hirsch
Publikováno v:
HistopathologyReferences. 81(1)
Malignant mesothelioma (MM) of the tunica vaginalis (TV) is a rare and aggressive tumour, and the molecular features and staining profile with contemporary immunohistochemical (IHC) biomarkers are largely unexplored. We characterise the clinicopathol
Publikováno v:
11th International Conference on Renewable Power Generation - Meeting net zero carbon (RPG 2022).